FuelCell Energy Inc vs Merck & Co., Inc. — how do they compare? FuelCell Energy Inc trades at $17.61 (market cap $1.47B), while Merck & Co., Inc. trades at $141.84 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 239.7× FuelCell Energy Inc's market cap, and Merck & Co., Inc. pays a 2.38% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Merck & Co., Inc. for 98 Days on average.
| FCEL | MRK | |
|---|---|---|
Market Cap | $1.47B | $352.29B |
Volume | 12,559,948 | 6,348,796 |
Sector | Industrials | Health |
52-Week High | $36.01 | $156.43 |
52-Week Low | $6.00 | $82.49 |
Typical Hold Time | 48 Days | 98 Days |
Enterprise Value | $1.05B | $399.05B |
Dividend Yield | — | 2.38% |
Signals from Pluang's Aura AI — not financial advice
FCEL stock trades at $18.37, down 11.07% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $158.16M in 2025 but sustained a net loss of $187.90M, reflecting negative profit margins. Recent news highlights a securities class action lawsuit filed against the company, alleging disclosure failures between June and September 2026.
The outlook remains challenged by persistent losses and high cash burn, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include the class action litigation, execution on profitability, and reliance on financing activities to fund operations.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →